Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
11/2005
11/23/2005EP1596808A2 L-dopa amide derivatives and uses thereof
11/23/2005EP1596807A2 Immune regulation based on the targeting of early activation molecules
11/23/2005EP1596806A2 Compositions and methods for treating cancer using igsf9 and liv-1
11/23/2005EP1596805A2 Treatments for snoring using injectable neuromuscular stimulators
11/23/2005EP1596804A2 SOLUBLE FcyR FUSION PROTEINS AND METHODS OF USE THEREOF
11/23/2005EP1596767A2 Random and non-random alkylene oxide polymer alloy compositions
11/23/2005EP1596756A2 Absorption enhancing agents
11/23/2005EP1583499A3 A novel polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia
11/23/2005EP1377227B1 Vessel sealing instrument
11/23/2005EP1320372B1 Use of sulfatides for treating diabetes
11/23/2005EP1007060B1 Stable extract of hypericum perforatum l., a method for producing the same, and corresponding pharmaceutical preparations
11/23/2005EP1001797B9 Soya extract, process for its preparation and pharmaceutical composition
11/23/2005CN1701068A Novel compounds and their use
11/23/2005CN1700929A Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor
11/23/2005CN1700918A N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
11/23/2005CN1700894A Methods of treating dry eye disease with lantibiotics
11/23/2005CN1700859A Nodulisporic acid derivative spot-on formulations for combating parasites
11/23/2005CN1699363A Vla-4 inhibitors
11/23/2005CN1699350A Processes and intermediates for preparing anti-cancer compounds
11/23/2005CN1699346A Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
11/23/2005CN1698603A Pharmaceutical composition
11/22/2005US6967210 Multiple sclerosis, brain disorders, analgesics
11/22/2005US6967091 Lowering circulating free fatty acid levels in an individual by administering to polypeptide and carrier
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005CA2249336C Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
11/17/2005WO2005058251A3 Hla-dr-specific antibodies, compositions and methods
11/17/2005WO2005058246A3 Method for preparing radiolabeled thymidine
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005WO2005046622A3 Custom vectors for treating and preventing pancreatic cancer
11/17/2005WO2005041883A3 Reduction of unintended use of transdermal devices
11/17/2005WO2005041870A3 Composition and method for the treatment of eye disease
11/17/2005WO2005034857A8 Methods and compositions comprising diamines as new anti-tubercular therapeutics
11/17/2005WO2005030122A3 Inactivated host cell delivery of polynucleotides encoding immunogens
11/17/2005WO2005023204A3 Aromatic prodrugs of propofol, compositions and uses thereof
11/17/2005WO2005016264A3 Diamine derivatives of quinone and uses thereof
11/17/2005WO2005016227A3 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
11/17/2005WO2005013908A3 Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
11/17/2005WO2005009397A3 Human lymphocyte vaccine adjuvant
11/17/2005WO2005007096A3 Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
11/17/2005WO2005007088A3 Stabilized anthocyanin extract from garcinia indica
11/17/2005WO2005000241A3 Compositons and methods for topical administration
11/17/2005WO2005000234A3 Novel coronavirus inhibitors
11/17/2005WO2005000222A3 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
11/17/2005WO2004103316A3 Orp9, a novel therapeutic target for increasing hdl levels
11/17/2005WO2004098504A3 Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines and methods of treating tumors
11/17/2005WO2004084799A3 Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
11/17/2005WO2004082602A3 Carboxamide spirohydantoin cgrp receptor antagonists
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005WO2004073736A8 Attenuated strains of vibrio cholerae and lyophilised vaccines containing same
11/17/2005WO2004024087A3 Methods of diagnosing and treating hyperproliferative disorders
11/17/2005US20050256132 Use of ER selective NF-kB inhibitors for the treatment of sepsis
11/17/2005US20050255488 NTRK1 genetic markers associated with age of onset of Alzheimer's Disease
11/17/2005US20050255123 Chimeric ebola virus envelopes and uses therefor
11/17/2005US20050255042 On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
11/16/2005EP1595145A2 Methods for the treatment of renal cell carcinoma
11/16/2005EP1595142A2 Method for evaluating the efficacy of certain cancer treatments
11/16/2005EP1594969A2 Active immunization to generate antibodies to soluble a-beta
11/16/2005EP1594959A2 Novel therapeutic method and compositions for topical administration
11/16/2005EP1594854A2 Thiazolyl-based compounds useful as kinase inhibitors
11/16/2005EP1594849A2 Compounds, compositions, and methods
11/16/2005EP1594847A2 Substituted azole derivatives as therapeutic agents
11/16/2005EP1594839A2 Methode of manufacturing glimepiride and the respective intermediate
11/16/2005EP1594835A2 Method of preparation of heterocyclic molecules with pharmaceutical pharmaceutical excipient cosmeceutical agrochemical and industrial uses
11/16/2005EP1594575A2 Modulation of atp production or content in the hypothalamus
11/16/2005EP1594560A2 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
11/16/2005EP1594542A2 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
11/16/2005EP1594541A2 Method and compositions for the treatment of meconium aspiration syndrome
11/16/2005EP1594535A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
11/16/2005EP1594534A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
11/16/2005EP1594524A2 Use of tryptanthrin compounds for immune potentiation
11/16/2005EP1594519A2 Cytomodulating peptides for treating interstitial cystitis
11/16/2005EP1594517A2 Methods and compositions for the treatment of gastrointestinal disorders
11/16/2005EP1594512A2 Compounds for the treatment of viral infection
11/16/2005EP1594508A2 Novel bicyclic compounds and compositions
11/16/2005EP1594507A2 Novel antiherpes drug combinations
11/16/2005EP1594504A2 Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
11/16/2005EP1594501A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/16/2005EP1594496A2 Novel therapeutic method and compositions for topical administration
11/16/2005EP1594492A2 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/16/2005EP1594490A2 Treating androgen deficiency in female (adif)-associated conditions with sarms
11/16/2005EP1594489A2 A method of treating breast cancer with androgen receptor antagonists
11/16/2005EP1594488A2 Stabilized pharmaceutical compositions of safingol and methods of using the same
11/16/2005EP1594485A2 Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use
11/16/2005EP1594484A2 Pharmaceutical patch
11/16/2005EP1594474A2 Coated particles and pharmaceutical dosage forms
11/16/2005EP1594465A2 Compositions comprising a plurality of particles or agglomerates having a defined particle size
11/16/2005EP1594464A2 Compositions comprising a defined polysaccharide component
11/16/2005EP1594463A2 Compositions comprising a polysaccharide component and one or more coating layers
11/16/2005EP1594444A2 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
11/16/2005EP1594443A2 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins
11/16/2005EP1594442A2 Knockout identification of target-specific sites in peptides
11/16/2005EP1594441A2 Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
11/16/2005EP1594440A2 The selective and specific preparation of discrete peg compounds
11/16/2005EP1594439A2 REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
11/16/2005EP1594437A2 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
11/16/2005EP1594435A2 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
11/16/2005EP1594434A2 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
11/16/2005EP1594433A2 Cancer therapy sensitizer
11/16/2005EP1594432A2 Short immunomodulatory oligonucleotides
11/16/2005EP1594366A2 Fat substitutes
1 ... 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 ... 295